Screener
BridgeBio Pharma BBIO Deferred royalty obligations, net
Deferred royalty obligations, net at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:DeferredRoyaltyObligationNet.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| 2031 Notes, net | 565,045 | 564,565 |
| 2029 Notes, net | 741,402 | 740,890 |
| 2027 Notes, net | — | 547,015 |
| Deferred royalty obligations, net (3) | 871,185 | 855,030 |
| Operating lease liabilities, net of current portion | 14,216 | 3,811 |
| Deferred revenue, net of current portion | 11,776 | 13,080 |
| Other long-term liabilities | 229 | 244 |
| Total liabilities | 3,639,856 | 3,012,606 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's deferred royalty obligations, net?
- BridgeBio Pharma (BBIO) reported deferred royalty obligations, net of $871.19M in Q1 2026.
- How has BridgeBio Pharma's deferred royalty obligations, net changed year-over-year?
- BridgeBio Pharma's deferred royalty obligations, net increased by 75.2% year-over-year, from $497.3M to $871.19M.
- What does deferred royalty obligations, net mean?
- This represents the net liability associated with future royalty payments that have been monetized or financed upfront. It reflects the company's obligation to share future product revenues with third-party financiers. This is a common financing tool used by biotech firms to fund R&D without immediate equity dilution.
Ask your AI about BridgeBio Pharma's deferred royalty obligations, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude